Donner Corp. International Issues Speculative Buy Recommendation On Advanced Tissue Sciences
IRVINE, Calif., Oct. 2 /PRNewswire/ -- The following is being issued by Donner Corp. International, a member of the National Association of Securities Dealers, CRD number 37702:
Donner Corp. International, an Investment Banking firm headquartered in Irvine, Calif., today issued a Speculative Buy Recommendation on Advanced Tissue Sciences, Inc. (Nasdaq: ATIS), headquartered in San Diego, Calif.
In the report, Donner Corp. cited Advanced Tissue Sciences' innovative technology for the development of human-based, scientifically engineered tissue. The report said the technology developed by Advanced Tissue Sciences eliminates many of the problems associated with the use of tissue from a cadaver or animal. ATIS "may provide the means to transport scientifically engineered tissue and organs from the realms of science fiction into the reality of our everyday lives."
The Donner report, by analyst Libby L. Weber, cites a strong product pipeline for Advanced Tissue Sciences, saying this provides "potential for sustained upside and a continued basis for growth." The report says the company is in the late-stage of clinical development of an engineered tissue product to address the problem of diabetic foot ulcers, from which 400,000 people in America suffer annually.
The Donner report concludes that it believes "ATIS stock is undervalued" partially because the company already has one successful approved product and a partnership with a leading worldwide healthcare company that has extensive experience in developing and marketing tissue repair products.
Copies of the report are available from Donner Corporation at 800/324-6050.
SOURCE Donner Corp. International
CO: Donner Corp. International; Advanced Tissue Sciences, Inc.
ST: California
IN: FIN MTC
SU:
10/02/98 09:10 EDT prnewswire.com
To edit your profile, go to keyword NewsProfiles.
For all of today's news, go to keyword News. |
